By the Top Tier Newswire AI Desk · August 5, 2026 at 10:21 AM ET · reviewed against 12 wire stories
INSULET CORP (PODD) is down -17.57% in the latest session. Our newswire has captured 12 stories on PODD across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
PODD stock fell 17.57% to $137.51 in early trading on August 6, 2026, following Insulet Corporation's announcement of a reduced sales growth forecast for the remainder of the year. The company cited slower-than-expected US insulin-pump sales as the primary reason for the downward revision. The stock opened at $162.60, but quickly declined to a session low of $126.40 before settling near $137.51.
What Happened
Insulet Corporation issued a revised sales forecast for the remainder of 2026, lowering its full-year guidance from $3.277B to $3.331B to $3.250B to $3.304B. This move came despite strong second-quarter results, which included a 23.5% revenue increase and a non-GAAP EPS of $1.66 that beat estimates. The company attributed the slower growth to challenges in US insulin-pump sales. The SEC 8-K filing on August 5 confirmed the results and outlook change. A class-action lawsuit was also announced, alleging misleading statements over a 16-month period preceding recent product corrections.
What The Data Shows
The stock opened with a -2.5% gap from the prior close and continued to decline sharply throughout the session. Volume reached 1.6 million shares, 1.1 times the 3-month average. The stock is currently trading within its 52-week range of $138.79 to $354.88. Despite recent insider purchases totaling $898,000 in the last 90 days, the stock has fallen from a high of $167.36 to $137.51 over the last eight sessions. Congressional trades show mixed activity, with three buys and four sells reported in the same period.
What To Watch
Insulet’s Q3 sales guidance of $829.9M to $844.0M is set to be compared against the $845.5M estimate. Continued coverage from analysts and updates on product corrections will be key to monitoring the stock’s next move.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PODD · Aug 5 session (5-min) · -20.94% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 12 stories · 46/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5d agoPR NewswireBEARISH 28General
Lost Money on Insulet Corporation (PODD)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Key Dates and Disclosure Events Insulet Corporation Shareholders Need to Know: A 16-Month Pattern of Manufacturing Quality and Product Safety Representations Preceded Two Omnipod Medical Device Corrections and Approximately $24 Per Share in Combined Immediate Stock Declines NEW YORK, Aug....
2026-08-05. The following slide deck was published by Insulet Corporation in conjunction with their 2026 Q2 earnings call.
5d agoInvestors.comBEARISH 28Earnings
Why Investors Took A Hammer To These Two Medical Stocks
Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump in the back half of the year.
5d agoReutersBEARISH 34Earnings
Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
5d agoInvesting.com MarketsBEARISH 42General
Why is Insulet stock tumbling today?
Why is Insulet stock tumbling today?
5d agoMarketChameleonBULLISH 73Earnings
Insulet Delivers 23.5% Revenue Growth with Omnipod Expansion and Accelerated International Momentum
August 5, 2026
Insulet’s second quarter results spotlight robust 23.5% revenue growth, surging international demand for its Omnipod insulin delivery systems, and a strategic innovation-driven outlook. This article breaks down Insulet’s financial performance, margin trends, and updated 2026 guidance—but also explores what’s fueling the company’s accelerating growth beyond numbers.
5d agoSeeking AlphaBULLISH 68Earnings
Insulet Non-GAAP EPS of $1.66 beats by $0.21, revenue of $801.7M beats by $14.27M
Insulet (PODD) Q2 earnings: EPS and revenue beat, Omnipod sales surge in U.S. and internationally, and margins shift.
5d agoSEC 8-KNEUTRAL 50General
INSULET CORP (PODD) files 8-K
Filed: 2026-08-05 AccNo: 0001145197-26-000167 Size: 505 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →